ArticleJCO oncology advances2025
Effect of Donepezil on Dimensions of Patient-Reported Cognitive Impairment in Breast Cancer Survivors: Secondary Analysis of the NCORP REMEMBER Trial (WF-97116).
Article in JCO oncology advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
purposeCancer-related cognitive impairment (CRCI) is a prevalent and persistent problem among many breast cancer survivors (BCS). Results from the randomized, placebo-controlled REMEMBER clinical trial (WF-97116) showed no improvement in cognitive test performance among BCS 1-5 years after chemotherapy after 24 weeks of daily donepezil compared with placebo. Here we present results for an important secondary outcome, patient-reported cognitive impairment, and explore the correlates of CRCI. PATIENTS AND
methodsWomen age ≥18 years with a history of breast cancer who completed ≥4 cycles of adjuvant cytotoxic chemotherapy 1-5 years before enrollment and self-reported CRCI were eligible. We enrolled participants through the Wake Forest National Cancer Institute Community Oncology Research Program (NCORP) Research Base and randomly assigned participants to a 24-week course of once daily donepezil (single 5 mg dose titrated to 10 mg after 6 weeks) or placebo. We administered the Functional Assessment of Cancer Therapy-Cognitive Function (FACT-Cog), a patient-reported outcome measure, at baseline and weeks 12, 24 (end of intervention), and 36 (wash-out). Mixed-effects repeated-measures analysis of covariance models assessed treatment differences in four FACT-Cog subscales. Additionally, demographic, clinical, and cognitive performance correlates of CRCI severity at baseline were examined.
resultsA total of 276 patients (mean age, 57.1; standard deviation, 10.5) from 87 NCORP sites were randomly assigned to donepezil (n = 140) or placebo (n = 136). There were no statistically significant treatment differences on the four CRCI outcomes: perceived cognitive impairments, cognitive abilities, impact on quality of life, and observations by others at 24 weeks. CRCI severity at baseline was associated with demographic variables, cognitive performance, and comorbidities, but not cancer-related variables.
conclusionThere were no discernible reductions in patient-reported CRCI attributable to donepezil, consistent with results for cognitive performance. CRCI severity appears to be multidimensional in nature, suggesting multifactorial prevention and treatment approaches might be beneficial.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.